INTRODUCTION
urological cancer, cancer, proteinuria, palmar‐plantar erythrodysesthesia syndrome, RCC, deaths
ADVERSE EVENTS, CANCER, UROLOGICAL CANCER, RCC
Renal cell carcinoma (RCC), the urological cancer with the highest mortality rate, accounts for 2% of global cancer diagnoses and deaths.Previous multicenter trials in patients with advanced RCC have shown more promising outcomes with tyrosine kinase inhibitors (TKIs) in combination with immune checkpoint inhibitors (ICI) than with TKI monotherapy.Previous studies of patients with advanced RCC treated with TKIs have revealed differences in drug tolerability profiles among Asian and non‐Asian populations. The incidence rates of certain adverse events (AEs), such as palmar‐plantar erythrodysesthesia syndrome and proteinuria, were reported to be higher in Asian populations compared with non‐Asian populations treated with sunitinib